-
AG-126: ERK Assay Design Beyond Pathway Labels
2026-08-28
AG-126 and Tyrphostin AG-126 provide a research tool for interrogating ERK1/2 phosphorylation, inflammatory signaling, and pathway-dependent phenotypes. This article connects its assay value to a neuroligin–striatal circuit study while clearly separating evidence from hypothesis.
-
QRICH1, ER Stress, and HMGB1 in HBV Fibrosis
2026-08-28
A 2025 Immunobiology study identifies QRICH1 as an important endoplasmic reticulum stress effector that amplifies HBV-associated HMGB1 transcription, translocation, and secretion. Its mouse-model and clinical-specimen data connect ER stress, SIRT6-dependent HMGB1 acetylation, and hepatic fibrosis while defining experimental readouts for studying this pathway.
-
Lisinopril Dihydrate: ACE Inhibition Workflows
2026-08-27
Lisinopril dihydrate provides a practical, water-soluble route to controlled ACE inhibition across enzyme, cellular, cardiovascular, and renal studies. This guide connects concentration planning with peptidase counterscreens, disease-model readouts, and troubleshooting strategies that improve interpretability.
-
Tunicamycin: A Practical N-Glycosylation Inhibitor Guide
2026-08-27
Tunicamycin provides a controllable way to connect disrupted protein N-glycosylation with ER stress, macrophage inflammatory signaling, and lymphocyte dysfunction. This guide translates the reference study into practical assay designs, dose-finding workflows, controls, and troubleshooting strategies.
-
p-Cresyl sulfate: Reliable Assay Workflows
2026-08-26
A scenario-based guide to using p-Cresyl sulfate (SKU A8895) in endothelial proliferation, wound-healing, viability, and cardiovascular disease models. It explains matrix effects, solution preparation, endpoint interpretation, and practical sourcing decisions for reproducible uremic toxin research.
-
Droplet Digital CRISPR-Cas13a for m6A Detection
2026-08-26
The reference study introduces a droplet digital CRISPR-Cas13a method for amplification-free detection of N6-methyladenosine (m6A) in RNA. By combining m6A-specific antibody enrichment with compartmentalized Cas13a analysis, the platform reports femtomolar sensitivity and quantitative estimation of methylation-site proportions without relying on PCR or isothermal amplification.
-
Eicosapentaenoic Acid (EPA) in Cell Assays
2026-08-25
A practical, evidence-based guide to using Eicosapentaenoic Acid (EPA) in cell viability, proliferation, cytotoxicity, and endothelial assays. It explains concentration selection, vehicle controls, handling, interpretation, and vendor qualification for SKU B3464.
-
Baicalein: Designing Mechanism-First Assays
2026-08-25
Baicalein is a 12-LOX-focused flavonoid for investigating cancer cell proliferation inhibition, apoptosis, and inflammation. This guide develops a paired assay strategy informed by a recent chemotherapy-neurotoxicity study, while clearly separating established evidence from testable research hypotheses.
-
Annexin V-Cy5 Apoptosis Kit Guide
2026-08-24
The Annexin V-Cy5 Apoptosis Kit supports rapid Annexin V apoptosis detection by labeling exposed phosphatidylserine with Cy5 for fluorescence microscopy or flow cytometry. It is useful as a membrane-level apoptosis assay, but it does not directly measure lysosomal digestion in stressed microglia.
-
ACE Inhibitor Selectivity Across Aminopeptidases
2026-08-24
Tieku and Hooper directly compared metallopeptidase inhibitors against the cell-surface aminopeptidases AP-A, AP-N, and AP-W, revealing substantial differences in inhibitor selectivity. The study shows why ACE inhibitor activity should not be inferred from potency against unrelated zinc aminopeptidases and provides a framework for evaluating off-target effects in peptide-metabolism research.
-
p-Cresyl Sulfate: From Uremia to Biliary Injury
2026-08-23
Explore how p-Cresyl sulfate, or p-tolyl hydrogen sulfate, connects renal retention, endothelial dysfunction, and biliary epithelial injury. This article translates recent mechanistic evidence into practical assay design decisions for integrated uremic toxin research.
-
BMN 673 (Talazoparib) PARP1/2 Inhibitor
2026-08-22
A practical, scenario-based guide to using BMN 673 (Talazoparib) for PARP-dependent viability, proliferation, and DNA-repair studies. It explains how SKU A4153 supports controlled dosing, assay interpretation, and reproducible compound selection across homologous-recombination-deficient and cancer cell models.
-
Catalpol Workflows for Neuroprotection Research
2026-08-22
Catalpol supports mechanism-led workflows spanning neuroinflammation, cognitive impairment, osteoporosis, ischemic stroke, and liver fibrosis models. This practical guide connects formulation, dosing, pathway validation, tissue exposure, and troubleshooting for more reproducible preclinical studies.
-
ATRX Loss and PDGFR Inhibitor Sensitivity in Glioma
2026-08-21
The 2022 Cancers study identified ATRX deficiency as a context associated with increased sensitivity of high-grade glioma cells to receptor tyrosine kinase and PDGFR inhibitors. Its most important translational implication is that ATRX status should be considered when interpreting RTK inhibitor trials and when designing combinations with temozolomide.
-
Muscle-Derived BDNF in Early NMJ Assembly
2026-08-20
The reference study shows that muscle-generated BDNF is a spatially controlled regulator of early neuromuscular junction assembly, rather than merely a diffusible trophic factor. By combining live-cell imaging, molecular perturbation, and skeletal muscle-specific knockout models, the authors connect BDNF trafficking, localized release, and proteolytic processing with acetylcholine receptor clustering.